Praxis Precision to file an NDA for relutrigine in encephalopathies in 2026 [Yahoo! Finance]
Praxis Precision Medicines, Inc. (PRAX)
Company Research
Source: Yahoo! Finance
Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now See the top stocks recommended by analysts Read More on PRAX: Disclaimer & Disclosure Report an Issue Praxis Precision achieves alignment on elsunersen pathway following FDA meeting Praxis Precision price target raised to $450 from $300 at Jefferies Praxis Precision Medicines: Promising Epilepsy Portfolio Advances Justify Buy Rating Praxis Precision price target raised to $760 from $540 at Guggenheim Praxis Precision Medicines Shares RADIANT Study Results
Show less
Read more
Impact Snapshot
Event Time:
PRAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRAX alerts
High impacting Praxis Precision Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
PRAX
News
- Praxis Precision Medicines (NASDAQ:PRAX) was given a new $313.00 price target on by analysts at Deutsche Bank Aktiengesellschaft.MarketBeat
- Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 [Yahoo! Finance]Yahoo! Finance
- Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026GlobeNewswire
- Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic EncephalopathyGlobeNewswire
- Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..MarketBeat
PRAX
Earnings
- 11/5/25 - Beat
PRAX
Sec Filings
- 12/11/25 - Form 8-K
- 12/8/25 - Form 8-K
- 11/21/25 - Form 4
- PRAX's page on the SEC website